Nature Reviews Clinical Oncology
(NAT REV CLIN ONCOL) 《自然评论：临床肿瘤学》
From ASCO—immunotherapy: Programming cancer cell death | PDF (173 KB)
p427 | doi:10.1038/nrclinonc.2012.104
Gastrointestinal cancer: A step closer to combating acquired resistance in CRC | PDF (218 KB)
p428 | doi:10.1038/nrclinonc.2012.114
Targeted therapies: Hepatocyte growth factor—a culprit of drug resistance |PDF (136 KB)
p429 | doi:10.1038/nrclinonc.2012.124
Metabolism: Craving for glycine | PDF (45 KB)
p430 | doi:10.1038/nrclinonc.2012.103
From ASCO—breast cancer: EMILIA trial offers hope | PDF (45 KB)
p430 | doi:10.1038/nrclinonc.2012.105
Targeted therapies: Match-and-mix or match-and-miss? | PDF (45 KB)
p430 | doi:10.1038/nrclinonc.2012.119
From ASCO—lymphoma: Bendamustine and rituximab triumphs as first-line therapy | PDF (45 KB)
p428 | doi:10.1038/nrclinonc.2012.107
From ASCO—urological cancer: Continuous dosing is preferred option for prostate cancer | PDF (45 KB)
p428 | doi:10.1038/nrclinonc.2012.108
From ASCO—skin cancer: BRAF kinase inhibitor shows efficacy in brain metastases | PDF (45 KB)
p428 | doi:10.1038/nrclinonc.2012.109
From ASCO—targeted therapies: Tivantinib shows promise in hepatocellular carcinoma | PDF (45 KB)
p428 | doi:10.1038/nrclinonc.2012.110
Screening: Confirming the benefits of screening in colorectal cancer | PDF (45 KB)
p429 | doi:10.1038/nrclinonc.2012.115
Breast cancer: Changing tumours, changing markers | PDF (45 KB)
p429 | doi:10.1038/nrclinonc.2012.116
Gynaecological cancer: Infertility and ovarian cancer | PDF (45 KB)
p429 | doi:10.1038/nrclinonc.2012.117
Combination therapy: Radiotherapy and immunotherapy, perfect match |PDF (45 KB)
p429 | doi:10.1038/nrclinonc.2012.118
NEWS AND VIEWS
Targeted therapies: Pazopanib for soft-tissue sarcoma: a PALETTE of data emerges
Isabelle Ray-Coquard & David Thomas
p431 | doi:10.1038/nrclinonc.2012.113
The PALETTE randomized phase III trial has reported a statistically significant benefit for the use of pazopanib compared to placebo in terms of progression-free survival for the treatment of soft-tissue sarcoma. However, no benefit in terms of overall survival was observed, the reasons for which might lie in the study design.
Radiotherapy: Radioiodine in thyroid cancer—how to minimize side effects
Christoph Reiners & Markus Luster
p432 | doi:10.1038/nrclinonc.2012.101
Life expectancy of most patients with differentiated thyroid cancer is normal, so adverse treatment effects should be minimized. Lower activities of radioiodine for ablation of thyroid remnants are non-inferior to higher activities and quality of life can be maintained by preparation of radioiodine remnant ablation using recombinant human thyrotropin.
Lung cancer: Locally advanced NCSLC in the elderly: which treatment?
p434 | doi:10.1038/nrclinonc.2012.112
Treatment of locally advanced non-small-cell lung cancer (NSCLC) in the elderly is challenging, with many available treatment options from radiotherapy alone to sequential chemoradiation. The latest phase III trial comparing radiotherapy alone with concurrent chemoradiation reported a survival improvement for the combination; however, this does not define a new standard treatment.
Thrombosis and cancer
Annie Young, Oliver Chapman, Carole Connor, Christopher Poole, Peter Rose & Ajay K. Kakkar
p437 | doi:10.1038/nrclinonc.2012.106
Venous thromboembolism (VTE) is a potentially life-threatening condition that can be associated with significant morbidity and is linked to cancer by numerous pathophysiological mechanisms. Here, the risk factors, mechanisms, prevention, and optimal treatment of VTE in patients with cancer are discussed.
State of the art in the treatment of Hodgkin lymphoma
Peter Borchmann, Dennis A. Eichenauer & Andreas Engert
p450 | doi:10.1038/nrclinonc.2012.91
Hodgkin lymphoma has become one of the most successfully treatable cancers; nevertheless, adverse treatment-related side effects still occur. In this Review, Borchmann et al. discuss the current choices for patients with Hodgkin lymphoma by finding the balance between optimal disease control and the risk of long-term sequelae.
Breast cancer in young women
Steven A. Narod
p460 | doi:10.1038/nrclinonc.2012.102
Breast cancers in young women are typically aggressive and so young age can correlate with a poorer outcome. In this Review article, Steven Narod discusses the risk factors, risks of recurrence and secondary cancer, treatment, prevention and awareness of very-early onset breast cancer.
Reducing the toxicity of cancer therapy: recognizing needs, taking action
Charles S. Cleeland, Jeff D. Allen, Samantha A. Roberts, Joanna M. Brell, Sergio A. Giralt, Aarif Y. Khakoo, Rebecca A. Kirch, Virginia E. Kwitkowski, Zhongxing Liao & Jamey Skillings
p471 | doi:10.1038/nrclinonc.2012.99
A multidisciplinary colloquium—Developing Strategies for Reducing Cancer Treatment-Related Toxicities and Symptoms—was held to identify the challenges that have prevented progress in reducing cancer-treatment-related symptom burden and to develop strategic steps to meet these challenges. This Perspectives article summarizes the recommendations of the panel, and includes suggestions for improving cancer care in the clinic and developing a policy and advocacy strategy to expand research on toxicity.
Tumour molecular profiling for deciding therapy—the French initiative
Frédérique Nowak, Jean-Charles Soria & Fabien Calvo
p479 | doi:10.1038/nrclinonc.2012.42
The use of tumour molecular profiles for therapeutic decision making requires that molecular diagnostics be introduced into routine clinical practice. To this end, the French National Cancer Institute and French Ministry of Health have set up a national network of 28 regional molecular genetics centres. In this Perspectives article, the authors look at the 4-year history of the French initiative and discuss its success in rapidly implementing molecular tests for new tumour biomarkers.